Treatment of resected non-small-cell lung cancer

被引:0
作者
Bria, E [1 ]
Giannarelli, D [1 ]
Terzoli, E [1 ]
机构
[1] Regina Elena Inst Canc Res, I-00144 Rome, Italy
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1523 / 1523
页数:1
相关论文
共 50 条
[31]   A REVELation in non-small-cell lung cancer treatment? [J].
Mok, Tony S. K. ;
Loong, Herbert H. .
LANCET, 2014, 384 (9944) :640-642
[32]   Trastuzumab for the treatment of non-small-cell lung cancer [J].
Ferrone, M ;
Motl, SE .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (12) :1904-1908
[33]   The systemic treatment of non-small-cell lung cancer [J].
Propper, D ;
Talbot, DC .
ANNALS OF ONCOLOGY, 1997, 8 (03) :285-290
[34]   Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer [J].
Wu, Yi-Long ;
Dziadziuszko, Rafal ;
Ahn, Jin Seok ;
Barlesi, Fabrice ;
Nishio, Makoto ;
Lee, Dae Ho ;
Lee, Jong-Seok ;
Zhong, Wenzhao ;
Horinouchi, Hidehito ;
Mao, Weimin ;
Hochmair, Maximilian ;
de Marinis, Filippo ;
Migliorino, M. Rita ;
Bondarenko, Igor ;
Lu, Shun ;
Wang, Qun ;
Ochi Lohmann, Tania ;
Xu, Tingting ;
Cardona, Andres ;
Ruf, Thorsten ;
Noe, Johannes ;
Solomon, Benjamin J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14) :1265-1276
[35]   Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].
Vozy, A. ;
Zalcman, G. .
ONCOLOGIE, 2015, 17 (09) :407-408
[36]   Gemcitabine for the treatment of non-small-cell lung cancer [J].
Johnson, DH .
ONCOLOGY-NEW YORK, 2001, 15 (03) :33-39
[37]   Crizotinib in the treatment of non-small-cell lung cancer [J].
Forde, Patrick M. ;
Rudin, Charles M. .
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) :1195-1201
[38]   Vandetanib for the treatment of non-small-cell lung cancer [J].
Wong, Hui-li ;
de Boer, Richard H. .
EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (14) :2271-2278
[39]   Multimodal treatment of non-small-cell lung cancer [J].
Eberhardt, Wilfried E. E. ;
Stuschke, Martin .
LANCET, 2015, 386 (9998) :1018-1020
[40]   Nintedanib for the treatment of non-small-cell lung cancer [J].
Rashdan, Sawsan ;
Hanna, Nasser .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (05) :729-739